iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System酶试剂盒Takara Clontech

上海金畔生物科技有限公司代理Takara酶试剂盒全线产品,欢迎访问官网了解更多产品信息和订购。

iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
品牌 Code No. 产品名称 包装量 价格(元) 说明书 数量
Cellartis Y30055 Cellartis® iPS Cell to Hepatocyte Differentiation System 1 Kit ¥15,704 iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
Cellartis Y30051 Cellartis® Hepatocyte Maintenance Medium 100 ml ¥2,521 iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
收藏产品 加入购物车
iPS向肝脏细胞定向分化操作系统
(Cellartis iPS Cell to Hepatocyte Differentiation System)
以肝脏细胞为模型的实验越来越受到重视,在肝脏病变机理研究、药物代谢研究、药物毒理评估等方面有广阔的应用前景。然而,以个体原代肝细胞为材料来源会产生如取材困难、材料批间差大、无法长期稳定供应等一系列难以克服的问题。因此,通过iPS批量转化生产肝细胞的方法就显示出特别的优势。Cellartis iPS Cell to Hepatocyte Differentiation System可以稳定地、规模化地实现iPS向hepatocyte的诱导转化生产,而且诱导转化出的肝细胞能够稳定表达药物代谢相关酶系统和药物转运系统。
Cellartis iPS Cell to Hepatocyte Differentiation System是一套Do-It-Yourself系统,客户既可以对某个特殊病人来源的iPS实现转化,也可以利用cellartis供应的iPS进行标准化操作。使用本产品的过程起始于诱导人iPS转化成为确定性内胚层(Definitive Endoderm (DE))细胞,然后诱导转化DE至肝细胞。本产品是All-In-One型产品,实验所需的培养基、基质(coating)等包括在内。应用本产品转化约3 × 106 hiPS cells,可以获得约5 × 106 肝细胞(大约50 cm2面积的单层贴壁细胞)。
利用Cellartis iPS Cell to Hepatocyte Differentiation System转化得到的肝细胞除了清晰表现出肝细胞的必备特征外(如肝细胞特异性标志物、CYP系列酶等),还保留了原始细胞供体者的遗传基因背景。另外,相比较从组织切除获得的原代肝脏细胞(通常需要低温保存),通过本产品系统转化获得的肝细胞在更长的时间跨度上保持着生理功能的稳定性。这一点对于毒理学评估和病毒感染评估具有显著的意义。为长时间维持培养hiPS转化而来的肝细胞,我们推荐Cellartis Hepatocyte Maintenance Medium (Cat. No. Y30051)。
 
关于Cellartis 卓越的iPS Cell to Hepatocyte Differentiation技术的专项说明,请点击:
详情
 
■ 产品特点
· Highly reproducible, robust system—the exact same protocol has been shown to work across 25 different iPS cell lines, so no need to optimize for your lines.
· Ideal for drug metabolism and safety studies—consistently generate panels of >90% pure, functional, hiPS cell-derived hepatocytes with diverse genetic backgrounds.
· Customized starting materials—start with any disease-relevant iPS cell lines and create accurate liver disease models.
· Ready for personalized medicine—make patient-specific, disease-specific cells for therapeutic applications.
· Extended experimental window—hepatocytes can be used for a minimum of 11 days for functional tests.
 
■ 产品成分
· Cellartis DEF-CS 100 Culture System (Y30020, not sold separately)
· Cellartis Definitive Endoderm Differentiation Kit (Y30030, not sold separately)
· Cellartis Hepatocyte Differentiation Kit (Y30050)
 
■ 产品详情请点击:iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
 
iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
Immunocytochemistry analysis of hepatocyte differentiation. hiPS cells were differentiated into functional hepatocytes using the Cellartis iPS Cell to Hepatocyte Differentiation System. Hepatocytes were immunostained to detect early hepatic markers HNF4α (red, nuclear) and CK18 (green) on days 14 and 21. As the hepatocytes matured, expression of liver-specific markers CYP3A (red, cytoplasmic) and Albumin (green) increased as seen on day 28, as expected. Cell nuclei were stained with DAPI (blue).
 
参考文献:
Asplund, Annika, et al.One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying? Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells. Stem Cell Rev and Rep (2015).
 
用户分享:
◆ 东海大学医学部-纸谷聪英教授
   利用人iPS细胞体外构建多囊性肝病(Polycystic liver disease)模型
 
iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
纸谷聪英教授使用Cellartis iPS Cell to Hepatocyte Differentiation System(Y30055)构建肝脏疾病模型的研究成果已刊登在Stem Cell Research。
【论文】
Akihide, K., Hiromi, C., Kinuyo, I., Emi, A., Kota, T., & Tatehiro, K., et al. (2018). An in vitro model of polycystic liver disease using genome-edited human inducible pluripotent stem cells. Stem Cell Research, 32, 17-24.
 
实验数据
 
iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
 
图:使用 Cellartis iPS Cell to Hepatocyte Differentiation System(Y30055)获得的人iPSC来源肝前体细胞(iPS-HPCs)诱导分化为胆管状Cyst结构。
(引用自文献Akihide Kamiya et al., Stem Cell Research, 2018)
 
访谈时间:
1. 开始使用Cellartis iPS Cell to Hepatocyte Differentiation System(Y30055)的契机是什么?
很多研究组已经报道了多种从人iPS细胞诱导分化形成肝脏细胞的方法,我们研究组也在做相关工作。由于细胞分化不稳定,我担心使用饲养层细胞培养人iPS细胞会对肝脏分化产生影响,因此决定尝试使用Cellartis iPS细胞无饲养层培养系统Cellartis DEF-CS™ 500 Culture System(Y30010)和肝脏分化系统Cellartis iPS Cell to Hepatocyte Differentiation System(Y30055)。
 
2.实际使用后感觉如何?
与之前使用的饲养层培养方法相比,Y30010能更简便高效的进行培养;使用Y30055进行的肝脏分化非常稳定,进一步提升了实验效率。
 
3. 对暂未使用该制品的用户有什么寄语?
人iPS细胞向肝脏细胞分化过程中,细胞密度对分化效率有很大影响,进而影响实验结果。我认为Cellartis系统的优点主要在于各个实验阶段偏差小,结果稳定,适合追求实验效率的人。
 
 
◆ 东京医科齿科大学-柿沼晴教授
   先天性肝纤维化模型的开发和病理阐明的研究
 
iPS向肝脏细胞定向分化操作系统iPS Cell to Hepatocyte Differentiation System
柿沼晴教授使用Cellartis iPS Cell to Hepatocyte Differentiation System(Y30055)构建肝脏疾病模型的研究成果已刊登在Journal of Hepatology。
 
【论文】
Tsunoda, T., Kakinuma, S., Miyoshi, M., Kamiya, A., Kaneko, S., & Sato, A., et al. (2019). Loss of fibrocystin promotes interleukin-8-dependent proliferation and ctgf production of biliary epithelium. Journal of Hepatology.
 
访谈时间:
1.开始使用Cellartis iPS Cell to Hepatocyte Differentiation System(Y30055)的契机是什么?
一起进行研究的老师使用后能够进行稳定的培养,我们研究室也正好想利用无饲养层培养系统,所以开始使用了Cellartis DEF-CS™ 500 Culture System(Y30010)和肝脏分化系统Cellartis iPS Cell to Hepatocyte Differentiation System(Y30055)。
 
2.实际使用后感觉如何?
Y30010无饲养层培养系统使用比较简便,同时能够稳定的培养人iPS细胞。这次实验中,利用Y30055分化至肝前体细胞(iPS-HPCs),进一步诱导分化成了胆管细胞,我认为诱导分化的再现性好。不仅分化至成熟肝细胞谱系,同时相比于以往报道的方法,再现性更稳定。
 
3. 对暂未使用该制品的用户有什么寄语?
在人iPS细胞的培养和分化至肝细胞谱系的诱导中,即使是对人iPS细胞使用经验尚浅的实验者,也能够进行培养并得到稳定的再现。
 
 

页面更新:2024-02-29 10:59:23